FierceBiotechFierceBioResearcherFierceBiotechITFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Vaccine | PPV | Pnuemovax 23 | Merck | CDC

CDC expands recommendations for Merck's PPV vax

Tools
  • Email
  • Print
  • Comment
  • Contact Author
  • Reprint

Adults smokers ages 19 to 64, or those in that age group with asthma, should receive the pneumococcal polysaccharide vaccine (PPV), according to the CDC's Advisory Committee on Immunization Practices (ACIP). The ACIP voted unanimously to issue the recommendations after examining study data, which demonstrated that the risk for pneumococcal diseases among smokers, such as pneumonia and meningitis, is about four times the rate for non-smokers. Data also revealed an increased risk of pneumococcal diseases among people with asthma.

In addition to the vaccine, the panel also recommended that smokers receive smoking-cessation counseling. It's likely that the CDC will adopt the panel's recommendations, which means an estimated 35 million smokers will be directed to get the jab and counseling.

PPV, marketed in the U.S. by Merck as Pnuemovax 23, is the only pneumococcal vaccine approved in the U.S for adults. Novartis has a a pneumococcal vax expected to begin trials in 2010.

- check out the Merck release
- read the AP article for more

Related Articles:
Patients clamor for scarce Merck vaccine
One up, two down for Merck's vaccines

More stories about Vaccine   PPV   Pnuemovax 23   Merck   CDC  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.